CorMedix (CRMD) Income towards Parent Company (2010 - 2025)
CorMedix (CRMD) reported Income towards Parent Company of -$11.8 million for Q4 2025, down 187.47% on a YoY basis from $13.5 million in Q4 2024, and down 110.85% sequentially from $108.5 million in Q3 2025.
CorMedix (CRMD) Income towards Parent Company (2010 - 2025) Analysis & Trends
CorMedix (CRMD) has 16 years of Income towards Parent Company data on file, last reported at -$11.8 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 187.47% year-over-year to -$11.8 million; the trailing twelve-month figure through Dec 2025 stood at $139.3 million (up 876.67% YoY), and the FY2025 full-year result was $137.3 million, up 865.52% from the prior year.
- Income towards Parent Company retreated to -$11.8 million in Q4 2025, from $108.5 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $108.5 million in Q3 2025 to a low of -$17.3 million in Q1 2021.
- A 5-year average of $201598.9 and a median of -$8.4 million in 2021 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company sank 199.88% in 2021 and jumped 4001.2% in 2025, its largest moves.
- Tracing CRMD's Income towards Parent Company over 5 years: stood at -$9.7 million in 2021, then grew by 15.08% to -$8.2 million in 2022, then tumbled by 79.73% to -$14.8 million in 2023, then jumped by 191.26% to $13.5 million in 2024, then slumped by 187.47% to -$11.8 million in 2025.
- Business Quant data shows CRMD's Income towards Parent Company at -$11.8 million in Q4 2025, $108.5 million in Q3 2025, and $21.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | CorMedix | 4.95 Mn | -150.26 Mn | 107.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.78 Mn |
| Sep 30, 2025 | 108.53 Mn |
| Jun 30, 2025 | 21.86 Mn |
| Mar 31, 2025 | 20.64 Mn |
| Dec 31, 2024 | 13.46 Mn |
| Sep 30, 2024 | -2.78 Mn |
| Jun 30, 2024 | -14.15 Mn |
| Mar 31, 2024 | -14.47 Mn |
| Dec 31, 2023 | -14.75 Mn |
| Sep 30, 2023 | -9.74 Mn |
| Jun 30, 2023 | -11.27 Mn |
| Mar 31, 2023 | -10.57 Mn |
| Dec 31, 2022 | -8.21 Mn |
| Sep 30, 2022 | -6.85 Mn |
| Jun 30, 2022 | -7.60 Mn |
| Mar 31, 2022 | -8.16 Mn |
| Dec 31, 2021 | -9.67 Mn |
| Sep 30, 2021 | -8.57 Mn |
| Jun 30, 2021 | -4.63 Mn |
| Mar 31, 2021 | -17.26 Mn |